Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Z Tatar
SAT0117 Retention Rates of Adalimumab, Etanercept, and Infliximab as 1st- Or 2nd-Line Biotherapy for Rheumatoid Arthritis Patients in Daily Practice in Auvergne
Related publications
PMS23 Cost Per Treated Rheumatoid Arthritis (RA) Patient for Etanercept, Adalimumab and Infliximab: A Retrospective Claims Database Analysis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis
Journal of Managed Care Pharmacy
PMS66 Satisfaction With and Preference for Golimumab and Its Auto-Injector Among Rheumatoid Arthritis Patients Switched From Adalimumab or Etanercept
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Comparison of the Efficacy of the Tumour Necrosis Factor Blocking Agents Adalimumab, Etanercept, and Infliximab When Added to Methotrexate in Patients With Active Rheumatoid Arthritis
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Etanercept: Therapeutic Use in Patients With Rheumatoid Arthritis
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Adalimumab With or Without Methotrexate in Juvenile Rheumatoid Arthritis
New England Journal of Medicine
Medicine
Anti-Atherosclerotic Effects of Etanercept in Rheumatoid Arthritis Patients
Japanese Journal of Clinical Immunology
Treat-To-Target Concept Implementation for Evaluating Rheumatoid Arthritis Patients in Daily Practice
European Journal of Rheumatology
PMS82 US Treatment Patterns in Psoriatic Arthritis Newly Initiated on Etanercept or Adalimumab
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
